Protective effects of pregnancy during MS have led to clinical trials of estriol, the pregnancy estrogen, in MS. Since estriol binds to estrogen receptor (ER) beta, ER beta ligand could represent a "next generation estriol" treatment. Here, ER beta ligand treatment was protective in EAE in both sexes and across genetic backgrounds. Neuroprotection was shown in spinal cord, sparing myelin and axons, and in brain, sparing neurons and synapses. Longitudinal in vivo MRIs showed decreased brain atrophy in cerebral cortex gray matter and cerebellum during EAE. Investigation of ER beta ligand as a neuroprotective treatment for MS is warranted.
Introduction
Multiple sclerosis (MS) is a putative autoimmune disease targeting the central nervous system (CNS) leading to neurodegeneration. Currently approved treatments for MS were designed to modulate peripheral immune responses to decrease CNS inflammation. These treatments reduce relapse rates by about half compared to placebo treatment in clinical trials, with only modest effects on slowing permanent disability accumulation. Many MS treatments are relatively safe and well tolerated. More aggressive anti-inflammatory treatments reduce relapse rates further, but are associated with toxicities related in part to immunosuppression. Rather than escalating to more aggressive anti-inflammatory treatments for better long term disability outcomes, an alternative would be to combine relatively safe anti-inflammatory treatments with a neuroprotective treatment in patients with relapsing remitting MS (Voskuhl, 2016) . Such neuroprotective treatments may also benefit progressive MS patients.
"Bedside to Bench to Bedside" research is a way to capitalize on a known clinical observation, mechanistically dissect it at the laboratory bench, then translate basic findings back to the clinic in the form of a novel clinical trial (Voskuhl and Gold, 2012) . This approach has a clinical observation as its foundation. In contrast, "Bench to Bedside" research is based on a molecule or pathway thought to be involved in a disease mechanism, with trials designed to block this molecule. The latter approach carries risk that the molecule or pathway of interest may not ultimately be physiologically significant in humans with disease, since most biological processes involve redundant mechanisms and compensatory pathways. Blocking one molecule or pathway may not have a significant effect in complex diseases in humans. This is one reason why pharmaceutical company success rates are low compared to the number of lead candidates initially passing in vitro screening and in vivo preclinical models. The "Bedside to Bench to Bedside" approach mitigates this risk since it starts with a clinical observation known to be physiologically relevant. Mechanisms underlying clinical observations may involve several molecules and complementary pathways. A multifaceted approach may indeed be what is required to impact complex diseases. The "Bedside to Bench to Bedside" approach in drug development is a conceptual shift, since the "Bench to Bedside" approach has focused on the molecule first, with questions of physiologic relevance coming later.
A major clinical observation in MS is that pregnancy is protective (Confavreux et al., 1998) . Relapses are decreased by over 70% in the last trimester. Hormones and other factors change during pregnancy, each warranting consideration for mediating this protection. Estriol is an estrogen of pregnancy, distinct from estradiol of ovulatory cycles. It is made by the fetal placental unit and rises progressively during pregnancy to reach high levels in the last trimester (Lindberg et al., 1974) . Estriol was given to mice with experimental autoimmune
